Prostate cancer is a type of cancer that affects a lot of men, and as there is no cure for cancer yet, spotting the symptoms is important. One of the possible indicators of the disease is through another condition, according to a new report.
Express reports that jaundice may also be a possible symptom of prostate cancer among men. Jaundice is referred to as having a yellowish tinge in the skin, as well as the whites of the eyes. This is caused by issues with the liver, and this condition would mean that the cancer has already progressed and spread towards the liver, where there may be some problems with the bile duct or large parts of the liver that have already been affected.
Jaundice is not the only indication that the cancer has already affected the liver. Other indicators include a pain on the right side of the body, nausea, loss of appetite, weight loss, itchy skin, as well as a swollen tummy.
Another possible indicator of prostate cancer is found in the urine. Express also reports that seeing a pink, red, or brownish-red color in the urine may be a symptom of prostate cancer. This would mean that there is blood. The same applies if there is blood in the semen, as the prostate is responsible for the production of semen, the fluid that is carrying the sperm. According to Cancer News Today, finding blood in the urine is also known as hematuria, and it can indicate that the prostate cancer has progressed.
However, because these are merely symptoms, there is a big chance that it may indicate other conditions that are not as severe as prostate cancer. Still, in case these are seen, then it is highly advised to consult a doctor to get a proper diagnosis and treatment. The earlier this is detected, the more successful treatment will be.
Prostate cancer mainly affects men above the age of 50, and the usual time of diagnosis between men is from 65 to 69. The risk of developing prostate cancer increases among men if there is a family history of either prostate or breast cancer.


Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 



